Company intelligence / Profile preview
dGenThera
Durham, North Carolina, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
dGenThera has not yet reached clinical trial phases but is rapidly advancing preclinical studies on matched therapeutic and imaging agents utilizing At-211 for targeted alpha therapy, designed for improved safety, stability, and targeting of radiotherapeutics in oncology with a focus on brain cancers and other high-unmet-need malignancies[1][2][4].
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeTargeted radiotherapeuticTheranostic molecular pair
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Nusano
Beyond the preview
Go deeper on dGenThera.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dGenThera.